A Randomised, Double-blind, Placebo-controlled Study of the Safety, Pharmacokinetics and Exploratory Pharmacodynamics of AUT00206 for 28 Days as Adjunctive Therapy in Patients With Recently Diagnosed Schizophrenia
Latest Information Update: 08 Dec 2022
At a glance
- Drugs AUT 00206 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Autifony Therapeutics
- 01 Sep 2022 Results evaluating the effect of AUT00206 on dopaminergic function in schizophrenia and its relationship with symptom change, published in the Journal of Psychopharmacology
- 15 Sep 2020 Results of an analysis assessing the improves speech in noise recognition in patients with schizophrenia, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 08 Apr 2019 Status changed from active, no longer recruiting to completed.